Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They presently have a $22.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 166.34% from the stock’s previous close.

STOK has been the topic of a number of other research reports. Chardan Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, February 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Finally, HC Wainwright boosted their price target on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Trading Down 6.9 %

Stoke Therapeutics stock opened at $8.26 on Tuesday. The firm’s 50 day simple moving average is $9.50 and its 200 day simple moving average is $11.51. The firm has a market capitalization of $437.51 million, a PE ratio of -3.93 and a beta of 0.99. Stoke Therapeutics has a 1-year low of $5.60 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Research analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently made changes to their positions in the business. Barclays PLC boosted its stake in shares of Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after purchasing an additional 47,239 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Stoke Therapeutics by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after purchasing an additional 76,661 shares in the last quarter. State Street Corp boosted its stake in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after purchasing an additional 137,145 shares in the last quarter. RTW Investments LP boosted its stake in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after purchasing an additional 427,447 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after purchasing an additional 71,647 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.